sana biotechnology inc. - SANA
SANA
Close Chg Chg %
4.30 -0.64 -14.88%
Closed Market
3.66
-0.64 (14.88%)
Volume: 29.63M
Last Updated:
Jan 10, 2025, 4:00 PM EDT
Company Overview: sana biotechnology inc. - SANA
SANA Key Data
| Open $5.00 | Day Range 3.55 - 5.16 |
| 52 Week Range 1.52 - 12.00 | Market Cap $960.06M |
| Shares Outstanding 223.27M | Public Float 122.42M |
| Beta 1.45 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.41 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 12.82M |
SANA Performance
| 1 Week | 114.04% | ||
| 1 Month | 93.65% | ||
| 3 Months | -8.27% | ||
| 1 Year | -42.13% | ||
| 5 Years | N/A |
SANA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About sana biotechnology inc. - SANA
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
SANA At a Glance
Sana Biotechnology, Inc.
188 East Blaine Street
Seattle, Washington 98102
| Phone | 1-206-701-7914 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -283,255,000.00 | |
| Sector | Health Technology | Employees | 328 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
SANA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.808 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.335 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.151 |
SANA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -863,582.317 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SANA Liquidity
| Current Ratio | 3.311 |
| Quick Ratio | 3.311 |
| Cash Ratio | 3.241 |
SANA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -40.814 |
| Return on Equity | -72.00 |
| Return on Total Capital | -72.332 |
| Return on Invested Capital | -58.188 |
SANA Capital Structure
| Total Debt to Total Equity | 36.207 |
| Total Debt to Total Capital | 26.582 |
| Total Debt to Total Assets | 18.414 |
| Long-Term Debt to Equity | 31.617 |
| Long-Term Debt to Total Capital | 23.213 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Sana Biotechnology Inc. - SANA
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 10.17M | 17.91M | 27.73M | 30.86M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 10.17M | 17.91M | 27.73M | 30.86M | |
Depreciation
| 10.17M | 17.91M | 27.73M | 30.86M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +159.40% | +76.13% | +54.80% | +11.30% | |
Gross Income
| (10.17M) | (17.91M) | (27.73M) | (30.86M) | |
Gross Income Growth
| -159.40% | -76.13% | -54.80% | -11.30% | |
Gross Profit Margin
| - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 150.95M | 228.68M | 241.32M | 294.94M | |
Research & Development
| 122.68M | 178.27M | 169.76M | 221.64M | |
Other SG&A
| 28.27M | 50.41M | 71.56M | 73.30M | |
SGA Growth
| +58.07% | +51.49% | +5.53% | +22.22% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 136.93M | 110.31M | 3.51M | (32.66M) | |
EBIT after Unusual Expense
| (298.05M) | (356.91M) | (272.56M) | (293.14M) | |
Non Operating Income/Expense
| 844.00K | 981.00K | 3.09M | 9.89M | |
Non-Operating Interest Income
| 747.00K | 676.00K | 3.76M | 9.94M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (297.20M) | (355.93M) | (269.48M) | (283.25M) | |
Pretax Income Growth
| -108.09% | -19.76% | +24.29% | -5.11% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | (11.90M) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | 11.90M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (285.31M) | (355.93M) | (269.48M) | (283.25M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (285.31M) | (355.93M) | (269.48M) | (283.25M) | |
Net Income Growth
| -118.16% | -24.75% | +24.29% | -5.11% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (285.31M) | (355.93M) | (269.48M) | (283.25M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (285.31M) | (355.93M) | (269.48M) | (283.25M) | |
EPS (Basic)
| -1.5216 | -2.1386 | -1.4308 | -1.456 | |
EPS (Basic) Growth
| -117.96% | -40.55% | +33.10% | -1.76% | |
Basic Shares Outstanding
| 187.51M | 166.43M | 188.34M | 194.54M | |
EPS (Diluted)
| -1.5216 | -2.1386 | -1.4308 | -1.456 | |
EPS (Diluted) Growth
| -117.96% | -40.55% | +33.10% | -1.76% | |
Diluted Shares Outstanding
| 187.51M | 166.43M | 188.34M | 194.54M | |
EBITDA
| (150.95M) | (228.68M) | (241.32M) | (294.94M) | |
EBITDA Growth
| -58.07% | -51.49% | -5.53% | -22.22% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 10.00 | |
| Number of Ratings | 7 | Current Quarters Estimate | -0.238 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | -0.875 | |
| Last Quarter’s Earnings | -0.23 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.202 | Next Fiscal Year Estimate | -0.818 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 8 | 6 |
| Mean Estimate | -0.24 | -0.24 | -0.87 | -0.82 |
| High Estimates | -0.20 | -0.20 | -0.63 | -0.57 |
| Low Estimate | -0.30 | -0.31 | -1.23 | -1.31 |
| Coefficient of Variance | -18.31 | -20.13 | -22.99 | -31.81 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 4 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 3 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Sana Biotechnology Inc. - SANA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Sana Biotechnology Inc. - SANA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 6, 2025 | Susan D. Wyrick See Remarks | 153,946 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.65 per share | 254,010.90 |
| Jan 6, 2025 | Susan D. Wyrick See Remarks | 7,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Susan D. Wyrick See Remarks | 155,512 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 10, 2024 | Hans Edgar Bishop Director | 5,790,489 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 27, 2024 | Richard Charles Mulligan Director | 2,698,121 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $3.89 per share | 10,495,690.69 |
| Sep 27, 2024 | Richard Charles Mulligan Director | 2,848,121 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.08 per share | 11,620,333.68 |
| Jul 16, 2024 | Alise S. Reicin Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 16, 2024 | Patrick Yuhmin Yang Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 16, 2024 | Robert Taylor Nelsen Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 16, 2024 | Douglas G. Cole Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 16, 2024 | Michelle Renae Seitz Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 16, 2024 | Mary Agnes Wilderotter Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 16, 2024 | Joshua H. Bilenker Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Bernard J. Cassidy EVP & General Counsel | 44,167 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Douglas E. Williams EVP & President, R&D | 301,875 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Douglas E. Williams EVP & President, R&D | 67,083 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Bernard J. Cassidy EVP & General Counsel | 198,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Steven D. Harr President & CEO; Director | 900,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Steven D. Harr President & CEO; Director | 200,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Nathan Hardy EVP, Chief Financial Officer | 301,875 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |